| |
Figure 7. Knock down of distinct Dishevelled genes generates distinct somite phenotypes. A: In situ hybridization to MyoD at control stage 29/30. B: Injection of Dvl1+2MO cocktail yields shorter embryos that exhibit a disruption of the normal MyoD pattern. C: Dvl3 morphants are normal in length, but embryos exhibit diminished anterior MyoD expression. D: Stage 32, normal MyoD (purple) in situ hybridization and (D') 12/101 (green) antibody staining. E: In Dvl3 morphants, MyoD expression is reduced anteriorly but 12/101 (E') is maintained. 12/101 staining is increased at the somite boundaries (red arrows). F: Normal Myf5 expression (purple) within somites and along both epaxial and hypaxial somite edges and (F') normal 12/101 staining. G: Myf5 staining of the hypaxial and epaxial somite edges appears unaffected in Dvl3 morphants, but expression is lost within the somites, though 12/101 is maintained (G'). H: Control stage-13 in situ hybridization for MyoD. I: Sibling stage-13 Dvl3 morphant embryo in situ hybridized to MyoD (purple). J, L: Normal expression patterns of bHLH myogenic transcription factors; MyoD and Myf5 at stage 22. K, M: Reduced anterior expression of assayed myogenic markers in Dvl3 morphants at stage 22. |
